We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
74 hedge funds and large institutions have $437M invested in Dianthus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
52% more capital invested
Capital invested by funds: $288M → $437M (+$149M)
50% more call options, than puts
Call options by funds: $3K | Put options by funds: $2K
3% more funds holding
Funds holding: 72 → 74 (+2)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0.1% more ownership
Funds ownership: 4.52% → 4.62% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
74
Holders Change
+2
Holders Change %
+2.78%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
19
Reduced
18
Closed
10
Calls
$3K
Puts
$2K
Net Calls
+$1K
Net Calls Change
+$1K
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.12M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$1.5M |
| 3 |
Millennium Management
New York
|
+$1.46M |
| 4 |
Alkeon Capital Management
New York
|
+$1.17M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$758K |
